


Remarks

Claims 1-5, 8-38, and 40-52 have been cancelled. Claims 6 and 7 have been amended in response to the restriction requirement and to make them dependent from claim 53. New claims 53 and 54 have been added in an attempt to comply with the restriction requirement and to more precisely claim the invention. Applicants assert that claims 53 and 54 present no new matter. Basis for these new claims may be found at least on page 4, lines 5 and 11; page 5 line 4; page 7 lines 8-9; and page 11, lines 1-9 of the specification as originally filed.

Claim 53 embraces compounds where variable Y is benzothienyl and variable X is selected from n-propyl, i-propyl, n-butyl, i-butyl, and cyclohexylmethyl. Although not identical to any invention drawn by the examiner, the amended claims most closely align with the invention of Group III. All of the compounds encompassed by the amended claims share the following core structure:



where variable Y may only be benzothienyl. Applicants strongly assert that the claims, as amended fully meet the requirements of unity of invention. Furthermore, because variable X is limited to n-propyl, i-propyl, n-butyl, i-butyl, and cyclohexylmethyl, Applicants submit that these amended claims will not create an undue burden on the examiner.

Entry of the amendments and allowance of the claims are respectfully requested. Should the examiner find that the new claims still lack unity of invention, then Applicants elect, with traverse, the compound of Example 1 solely for purposes of examination. The compound of Example 1 is encompassed by all of the claims now pending.

Respectfully submitted,

/Robert D. Titus/

Robert D. Titus
Attorney for Applicants
Registration No. 40,206
Phone: 317-277-3729

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

October 23, 2007
